RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Gabaergic receptor subtype selective ligands and their uses

Cook, J. M., Clayton, T. S., Jain, H. D., Johnson, Y. T., Yang, J., Rallipalli, S. K., Wang, Z., Namjoshi, O. A., & Poe, M. M. (2015). Gabaergic receptor subtype selective ligands and their uses. (U.S. Patent No. US20150258128A1). https://patents.google.com/patent/US20150258128A1/en?oq=Cook%2c+J.+M.%2c+Clayton%2c+T.+S.%2c+Jain%2c+H.+D.%2c+Rallapalli%2c+S.%2c+Johnson%2c+Y.-T.%2c+Poe%2c+M.%2c+Namjoshi%2c+O.+A.%2c+%26+Wang%2c+Z.-J.+(2015).+Gabaergic+receptor+subtype+selective+ligands+and+their+uses.+U.S.+Patent+number+US2015%2f0258128A1.+Filed+March+03%2c+2015;+published+September+17%2c+2015

Abstract

Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

Download/Explore
Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.